Drug Discovery – Talk Bio

Insilico Medicine; TaiGen Biotechnology; license agreement; ISM4808; PHD inhibitor; anemia of Chronic Kidney Disease; CKD anemia; AI-driven drug discovery; Pharma.AI; Greater China rights; oral PHD inhibitor; IND clearance; China CDE; generative AI; clinical-stage biotech

Novartis and Relation Therapeutics form AI-driven, multi-program atopic disease collaboration

2 months ago talkbio0Tagged * * atopic diseases * *, * * functional cell, AI-powered, Asthma, atlases, Billion, Drug Discovery, Eczema, Hypersensitivity, IL13 gene, immuno-dermatology, Lab-in-the-Loop, milestones, multi-program collaboration, Novartis

Novartis; Relation Therapeutics; AI-powered drug discovery; Lab-in-the-Loop; atopic diseases; immuno-dermatology; multi-program collaboration; asthma; allergies; eczema; allergic rhinitis; $55 million upfront; $1.7 billion milestones; functional cell atlases

Nona Biosciences Appoints Dr. Hongjiang Miao as Chief AI Officer to Advance A³ Strategy and AI-Driven Drug Discovery

2 months ago2 months ago talkbio0Tagged Biotechnology, Chief AI Officer, Drug Development, Drug Discovery, Harbour Mice ® technology, Hongjiang Miao, integrated solutions, Nona Biosciences, Shanghai

Nona Biosciences; Hongjiang Miao; Chief AI Officer; AI-Driven Drug Discovery; biotechnology; Shanghai; drug development; Harbour Mice technology; integrated solutions

Rakovina Therapeutics Announces Q3 2025 Financial Results and Corporate Update

2 months ago talkbio0Tagged AI-powered, ATR Inhibitor, Clinical Nurse Specialists, Conferences, corporate milestones, development expenses, Ditiocarb, Drug Discovery, Eligibility Determination, financial results, Investments, NanoPalm joint-venture, net loss, Penetration, Q3, Rakovina, research

Rakovina Therapeutics; Q3 2025; financial results; net loss; research and development expenses; AI-powered drug discovery; ATR inhibitor; CNS penetration; corporate milestones; NanoPalm joint-venture; investment conference; DTC eligibility

As Drug Resistance Rises, GramEye and GSK Advance New AI-Led Infectious Disease Research

2 months ago talkbio0Tagged AI-driven, Antibiotics, Antimicrobial Resistance, Clinical Trials, Communicable Diseases, Drug Discovery, Gram-negative bacteria, GramEye, Mycoses, research, SmithKline Beecham, Staphylococcus aureus, superbugs

antimicrobial resistance (AMR); GramEye; GSK; AI-driven drug discovery; Gram-negative bacteria; Staphylococcus aureus; fungal infections; novel antibiotics; superbugs; infectious disease research; clinical trials